Neratinib in the context of an early breast cancer anti‑HER2 therapy


Prof. MUDr. Petra Tesařová, CSc.

Onkologická klinika 1. LF UK a VFN, Praha



Early breast cancer with human epidermal growth factor receptor 2 (HER2 [EGFR2]) positivity has a better chance of recovery due to the potential of targeted adjuvant and neoadjuvant anti-HER2 treatments. Nevertheless, 25% of patients who still have the disease, despite the treatment, remain mostly in the form of distant metastases. Therefore, it is sensible for patients at risk to enhance anti-HER2 treatment for early HER2 positive cancer. One option is prolonged adjuvant therapy with neratinib.


Key words

neratinib, loperamide, early HER2 positive breast cancer, adjuvant anti-HER2 therapy



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...